Abbott Laboratories Form 4 insider transactions

Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Andrea F. Wainer, Executive Vice President of Abbott Laboratories, reported disposing of 8,339 common shares on February 29, 2024.

Executive Vice President Daniel Gesua Sive Salvadori reports the disposition of Abbott Laboratories shares to cover tax obligations and a sale of shares on March 1, 2024.

Executive Vice President Louis H. Morrone of Abbott Laboratories reports the disposition of shares and updates to beneficial ownership.

Executive Vice President Mary K. Moreland reports the disposition and acquisition of Abbott Laboratories common shares, including shares withheld for tax obligations and shares sold on the open market.

Abbott Laboratories' Vice President, John A. McCoy, Jr., reports the disposition and acquisition of company stock, including sales to cover tax obligations.

Robert E. Funck, Jr., Executive Vice President of Abbott Laboratories, reports the disposal of 11,415 common shares to cover tax obligations.

Abbott Laboratories CEO Robert Ford disposed of 31,610 common shares to cover tax obligations, while still holding a significant number of shares directly and indirectly through a family trust.

Executive Vice President of Abbott Laboratories, Lisa D. Earnhardt, reports the disposition and acquisition of company stock.

Senior Vice President Philip P. Boudreau reports disposition of Abbott Laboratories shares to cover tax obligations.

Executive Vice President Hubert L. Allen reports the disposition of Abbott Laboratories shares on February 29, 2024, and March 1, 2024.

Executive Vice President of Abbott Laboratories, Andrea F. Wainer, reports exercising stock options and selling shares on February 23, 2024.